Biotech Stocks To Watch in 2023: PBIO, BYSI, NRSN, MXCT, OSUR

It is often noted that investors should not be looking at specific stocks at all times and instead choose to go for themes with regard to sectors. That is often a better way of going about things since it is possible for investors to then check a cluster of stocks related to one sector which may be performing well. Many of the stocks in the biotech sector remain in high demand for the simple reason that the future looks bright for the sector. This article is going to provide you with a quick look into 5 stocks from the biotech sector that could be worth tracking this year.

Pressure Biosciences Inc (OTCMKTS:PBIO) is a company that is involved in the development of pressure-based instruments that could be deployed across several industries. More importantly, the company is well known for having worked extensively on research and development and that is another factor that ought to be kept in mind when considering it as an investment.

In this regard, it should be noted that the PCT Platform is something that could well prove to be a long-term positive for the company. The PCT Platform is something that is applicable across a wide range of industries and that is one of the reasons why it is often regarded as a company worth watching.

Pressure Biosciences is a company which has as many as 300 PCT instruments that are placed in as many as 200 laboratories across the world. There are many publications all over the world which are involved in publishing information about the virtues of the platform on a daily basis.

On January 19, Pressure Biosciences announced that one of its partner companies in California, Crème de Canna, had been successful in testing a THC Nanoemulsion Oral Spray through the deployment of the Ultra Shear Technology platform. Crème de Canna is the company’s partner in California and is a manufacturer of repute. It is well-known for manufacturing innovative premium cannabis products in the state.

The product that was manufactured through the use of Ultra Shear Technology was tested on a number of groups and it was noted that it took effect within the 1 to 10 minutes range. Pressure Biosciences’ partners could start marketing the product in California during the current quarter.

Moreover, Pressure Biosciences released strong revenue guidance for Q4 2022. The company projects that the revenues could be higher than what it had ever achieved in the past four years.

The Company further believes Q1 2023 revenue will greatly exceed Q4 2022’s expected strong results, and that revenues in each successive quarter will be higher than the prior quarter’s level. UltraShear revenues are expected to top $10M for 2023, beginning with over $1M in Q1 2023.

Interestingly, Management expects the Company to reach break even/profitability by the end of 2023.

BeyondSpring (NASDAQ:BYSI) – The clinical biopharmaceutical company BeyondSpring is based out of New York and is involved in the development of innovative cancer therapies which could serve patients with unmet needs. At this point, the company is involved in developing the product plinalubin which could be potentially used for the treatment of various cancer indications.

On January 9, the company was in the news after it got a notification from NASDAQ with regards to the fact that it had regained compliance with the exchange’s listing rules.

NeuroSense Therapeutics Ltd (NASDAQ:NRSN) – Another company that may be worth tracking at this point is NeuroSense Therapeutics Ltd, which is involved in the development of treatments for those who may be suffering from debilitating neurodegenerative conditions.

Last week, NeuroSense Therapeutics was in the news after it announced positive results from its Alzheimer’s biomarker study. The higher levels of TDP-43 novel biomarkers displayed the fact that the company’s combination had the potential of treating the particular condition. It was a major development for the company and one that investors could keep an eye on.

MaxCyte (Nasdaq: MXCT) – One of the companies in the biotech sector which may deserve attention at this point is MaxCyte. The company is involved in the cell engineering sector and is involved in providing its expertise to promote the cause of cell therapies.

Investors who are interested in the sector could do well to keep an eye on the Maxcyte stock over the course of the coming days as the company goes from strength to strength.

OraSure Technologies (NASDAQ:OSUR) – Anyone who may be interested in the biotech sector could do well to consider tracking OraSure Technologies at this point.

The company has a presence across the world and is involved in providing medical experts with information daily. It operates its business through a range of fully owned subsidiary units.

Disclaimers: This article contains sponsored content. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. CaptalGainsReport ‘CGR’ which is owned by RazorPitch Inc, is responsible for the production and distributions of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR has been compensated by GSW Group Inc to produce and syndicate this content for PBIO. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website.